Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02910102 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
A Phase 2 study, sponsored by Axovant Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT02910102: Completed Phase 2 study, sponsored by Axovant Sciences.
NCT02910102 is a Phase 2 study that has completed, run by Axovant Sciences. The registered enrollment target is 38 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02910102, a Phase 2 study, has completed, sponsored by Axovant Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.
Primary Outcome
Change from baseline in gait speed (cm/sec) measured on an electronic walkway system under single task trial condition (meaning walking only) at the end of each two-week treatment period
Interventions
- DRUG Placebo
- DRUG RVT-101 35 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2016-10 |
| Est. Completion | 2017-11 |
| Phase | Phase 2 |
What the finished NCT02910102 record still lists
NCT02910102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02910102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02910102 about?
NCT02910102 is a clinical study titled "Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia". This study seeks to evaluate the effect of intepirdine (RVT-101) on gait and balance in patients with Alzheimer's Disease, Dementia with Lewy Bodies or Parkinson's Disease Dementia.
What is the current status of trial NCT02910102?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2016-10. Estimated completion is 2017-11.
What interventions are being tested in trial NCT02910102?
The interventions under investigation include: Placebo (DRUG), RVT-101 35 mg (DRUG).
Who is sponsoring clinical trial NCT02910102?
This trial is sponsored by Axovant Sciences, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02910102's enrollment target sits among peer trials
38 1467th of 2000 higher than 517 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia